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A widespread screening with prostate-speciﬁc antigen (PSA) has led increased diagnosis of localized prostate cancer along with
a reduction in the proportion of advanced-stage disease at diagnosis. Over the past decade, interest in focal therapy as a less
morbid option for the treatment of localized low-risk prostate cancer has recently been renewed due to downward stage migration.
Focal therapy stands midway between active surveillance and radical treatments, combining minimal morbidity with cancer
control. Several techniques of focal therapy have potential for isolated ablation of a tumor focus with sparing of uninvolved
surround tissue demonstrating excellent short-term cancer control and a favorable patient’s quality of life. However, to date, tissue
ablation has mostly used for near-whole prostate gland ablation without taking advantage of accompanying the technological
capabilities. The available ablative technologies include cryotherapy, high-intensity focused ultrasound (HIFU), and vascular-
targeted photodynamic therapy (VTP). Despite the interest in focal therapy, this technology has not yet been a well-established
procedure nor provided suﬃcient data, because of the lack of randomized trial comparing the eﬃcacy and morbidity of the
standard treatment options. In this paper we brieﬂy summarize the recent data regarding focal therapy for prostate cancer and
these new therapeutic modalities.
1.Introduction
Prostate cancer is one of the most common cancers in the
developed countries [1]. Statistically it has overtaken lung
and colon cancers to be the most common cancer in male.
One of the most important advances in prostate cancer
management in recent years is the discovery of prostate-
speciﬁc antigen (PSA) as a tumor marker [2]. A 75%
decrease in metastatic prostate cancer and a 91% increase
in localized disease with patients diagnosed annually have
been observed since 2002 [3]. That is, the PSA screening
has resulted in an increased detection rate of prostate
cancer with stage migration towards lower stage, leading
to overdetection and overtreatment of prostate cancer by
at least 30% [4, 5]. A dramatic diagnostic paradigm shift
has forced urologists to reevaluate the role of traditional
radical therapies such as external beam radiotherapy and
prostatectomy. Maintaining quality of life is as important as
prostate cancer eradication. Thus, it is no longer acceptable
to just cure prostate cancer patients by aggressive treatments
in downward grade and stage migration as well as declining
age of prostate cancer diagnosis. Because radical treatments
carry signiﬁcant morbidity with operative complications
(hemorrhage, pain, etc.) and long-term toxicity (inconti-
nence, impotence, rectal problems, etc.), there has been a
great need for developing ablative therapies that attempt to
reduce treatment burden with assuring good cancer control
and avoiding the psychological morbidity associated with
active surveillance. In addition, it seems reasonable that
interest has been considerable in adapting focal methods
because the prostate is easily accessible by way of the rectum,
urethra, or perineum. Partial surgery of the prostate is
impossible due to the location of the cancer in the periphery
of the prostate gland, which to access necessitates the
almost same morbidity as removing the whole gland. There-
fore, focal therapy using energy modalities oﬀers generally2 Advances in Urology
accepted only solution for partial treatment of the prostate
gland.
Focal therapy has been introduced as middle ground
alternativebetweenactivesurveillanceandradicaltreatments
with eﬀective early cancer cure or control. The terms “focal
therapy” and “organ-preserving therapy” may be deﬁned
as complete selectively ablation techniques of clinically
signiﬁcant cancer foci within prostate in a focal or subtotal
manner with the overall objective of minimizing lifetime
morbidity without compromising life expectancy. That is
to say, the energy modalities must be easily delivered to
the prostate and be capable of destroying cancer cells.
The obvious beneﬁt of focal therapy is preservation of the
uninvolved surround healthy tissues such as the sphincter,
the neurovascular bundles, and normal prostate gland using
a minimally invasive technique [6]. And there may be a
potential to repeat focal therapy or use another treatment
modality in case of persistent cancer. On the other hand,
the main issue of prostate cancer is multifocal localization of
cancer foci [6]. The patients with unifocal, unilateral, or low
volume prostate cancer are most suitable for focal therapy;
however, we found a great deal of diﬃculty in identifying
patients with multifocal clinically signiﬁcant cancer foci who
require aggressive whole gland therapy from those with
clinically focal cancers who may beneﬁt from organ-sparing
treatment. It has been reported that the oncological outcome
was similar between the unilateral or bilateral cancer groups
in patients with low-risk prostate cancer, suggesting that the
limiting factor for focal therapy is clinical risk stratiﬁcation,
not laterality of cancer [7]. Indeed prostate cancer has
long been recognized as characteristically multifocal, but it
may present as true unifocal or volume-limited multifocal
disease in the era of widespread PSA screening and early
detection. Therefore, improved imaging techniques and
mapping biopsy protocols in patient selection are needed to
fully support focal therapy.
In this paper we brieﬂy discuss the evidence for a variety
ofablativeenergymodalitiesavailableforuseinfocaltherapy
of localized prostate cancer including cryotherapy, high-
intensity focused ultrasound (HIFU), and vascular-targeted
photodynamic therapy (VTP).
2. Cryotherapy
The ﬁrst report describing cryotherapy of benign prostate
hyperplasia appeared in 1966 [8], and an attempt to
destroy prostate cancer by using a transperineally introduced
cryoprobe was reported in 1972 [9]. Although cryotherapy
did not achieve wide usage initially due to incomplete
eradication of the tumor or high recurrent rate of cancer
[10, 11] and high complication rates including urinary
retention, incontinence, urethrorectal or urethrocutaneous
ﬁstulas, stricture, chronic rectal or perineal pain, and loss
of erections, advantages of the procedure were recognized
[12]. In particular, use of transrectal ultrasound (TRUS)
for real-time monitoring of the freezing process, improved
cryoprobe system, and a urethral warmer using a continuous
irrigationsystemcouldpopularizecryotherapyasaneﬀective
and technically feasible treatment for prostate cancer [13].
Finally, cryotherapy was approved as treatment for prostate
cancer by Centers for Medicine and Medical Services in 1999
[14].
Cryotherapy is the localized destruction of tissue by low
temperature and thawing, which causes direct injury to cells
as well as secondary injury from the inﬂammatory response
of the body. Current technology uses argon gas or liquid
nitrogen circulating through hollow needles to freeze the
prostate and helium gas to warm the urethra via the Joule-
Thompson eﬀect. There are three treatment parameters
correlated with cancer cell destruction: the cooling rate, the
lower temperature, and the duration of the freeze cycle.
Complete cell death is likely to occur at temperatures
lower than −40◦C for two cycles. After reaching a tissue
temperature of less than 0◦C, the extracellular ﬂuid starts
to crystallize and formation of crystals causes hyperosmotic
pressure of the unfrozen portion of the extracellular ﬂuid
compartment,leadingtowatershiftingfromtheintracellular
space to the extracellular space. The cell water loss induces
intracellular dehydration and pH change. This is followed
by cell shrinkage and denaturing of cellular proteins. With
further drops in temperature less than −15◦C intracellular
crystallization takes place and cell metabolism begins to
fail. This mechanically breaks the cellular membrane and
the cell apoptosis is also induced after thermal injury. The
apoptotic cells are observed primarily in the peripheral zone
of the cryogenic lesion outside the killing zone, where the
temperature is not fully decreased to kill all the cells [15].
As temperatures rise, extracellular ﬂuid shifts back again
into the intracellular space, leading to cellular bursting. The
vasodilation around the targeted tissue occurs after thawing
causing hyperpermeability of the vessel wall. This leads to
endothelial damage and microthrombi formation resulting
in regional tissue hypoxia and secondary necrosis of the
tissue [14, 16].
A signiﬁcant current development is the introduction
of cryotherapy probes that use argon gas rather than liquid
nitrogen. Argon gas can rapidly cool the probe tip to
−187◦C and can be rapidly exchanged with helium gas
at 67◦C for an active thawing phase, producing a faster
response to operator input and signiﬁcantly speeding 2-
cycle treatment [17]. Moreover, argon-based probes have
a much smaller diameter. Thus, they permit direct, sharp
transperineal insertion using transperineal placement of
ultrathin probes through a brachytherapy template, avoiding
the need for tract dilation and facilitating more confor-
mal cryosurgery by allowing placement of more probes
[18].
3.PatientSelection
This modality can be used in any tumor grade of prostate
cancer with clinical stage T1c-T3 disease. In general, pri-
mary cryotherapy is suitable for patients with low-risk
group (clinical stage T1c-T2a disease, Gleason grade 6,
and PSA < 10ng/mL who are not potent or not interested
in maintaining their potency). Patients with intermediateAdvances in Urology 3
risk group (Gleason grade 7, PSA between 10 and 20, or
clinical T2b) are also eﬀective for the procedure. Because
of the minimally invasive therapeutic modality, cryotherapy
may have speciﬁc advantages in selecting patients with
certain comorbidity including those who cannot tolerate
radicalprostatectomyorradiationtherapy(e.g.,personswith
previous pelvic radiation or pelvic surgery, irritable bowel
disease, cardiac disease, extreme obesity) [14]. Contraindi-
cation to cryotherapy includes the presence of tumor foci
near the urethra because the urethral warming catheter will
preclude complete eradication of disease [16]. In addition,
this therapy is generally contraindicated in patients with the
presence of tumor foci near the neurovascular bundles if
patientsarepotentorinterestedinmaintainingtheirpotency
[16]. Patients with severe lower urinary tract symptoms or
large prostate are also poor candidates for cryotherapy, and
a previous transurethral resection of the prostate (TURP) is
generally considered a contraindication. If the prostate size
exceeds 50mL, neoadjuvant hormone therapy is needed to
reduce the prostate volume because complete freezing of the
prostate is diﬃcult [14, 19]. However, there is no evidence
whether neoadjuvant therapy or combination therapy with
androgen deprivation inﬂuences postcryotherapy cancer
control [14].
4. ClinicalOutcomes
There were a lack of consensus on how recurrence was
deﬁned and no accepted biochemical deﬁnition of PSA
failure after primary cryotherapy. The PSA value rises
immediately after cryotherapy due to release of intracellular
PSA from cellular necrosis and PSA nadir is usually achieved
more than 3 months after the procedure [20]. Serum PSA
levels are unlikely to reach undetectable levels because some
PSA-producing periurethral prostatic tissue will remain.
Commonly, in order to assess local control patients who
have been treated with cryotherapy have undergone repeat
prostate biopsy 6 to 12 months after cryotherapy in several
series. The positive biopsy rate after the procedure ranges
from 7.7% to 23% [13, 19, 21, 22]. These studies are
including focal targeted cryoablation, hemiablation, and
radical cryoablation. Higher initial PSA levels and clinical T
stage were positively associated with a risk of positive biopsy
rate after cryotherapy. In 860 patients treated with focal
cryotherapy included in the Cryo On-Line Data (COLD)
Registry, 5-year biochemical disease-free rates ranged from
77.6% to 82.4% according to the American Society for
Therapeutic Radiology and Oncology (ASTRO) criteria of
three consecutive PSA rises after the posttreatment nadir and
58.0% to 74.9% according to the Phoenix criteria of PSA
nadir plus 2. For this series, 21% had evidence of cancer at
postcryotherapybiopsy[23].Takentogether,resultsofrecent
reports indicate that 5-year biochemical disease-free survival
rates range from 60% to 90% for patients with low- and
intermediate-risk groups [24–27]. A recent randomized trial
to compare external beam radiotherapy to cryotherapy for
patients with localized prostate cancer receiving neoadjuvant
antiandrogen therapy indicated cryotherapy to be nonin-
ferior to external beam radiotherapy in disease progres-
sion (23.9% in cryotherapy versus 23.7% in radiotherapy)
at 36 months and 5 years overall (89.7% versus 88.5%) and
disease-speciﬁc survival at 5 years (96.4% versus 96.1%)
[28].
5. Complications
Erectile dysfunction and impotence after cryotherapy are
common.Someserieshavereportedimpotenceratesranging
from 50% to 92% [27, 29]. This is probably because of
the use of multiple freeze-thaw cycles and the extension
of the damage beyond the prostate, into the area of the
neurovascular bundles; however, complete ablation of the
neurovascular bundles is necessary to ensure eradication
of cancer at the periphery of the prostate. Interestingly,
impotence rates after hemiablation ranged from 10% to 29%
andpotencymadearecoverywithin1year,althoughsubtotal
or focal cryotherapy should be investigational [30, 31]. A
recent randomized trial reporting on quality of life outcomes
showed that cryotherapy was associated with poorer sex-
ual function comparing with external beam radiotherapy.
Patients who wish to increase their odds of retaining sexual
function may be better to choose other modalities over
cryotherapy [32]. Cryotherapy is associated with more acute
urinary dysfunction, which resolves over time [32]. The
reportedincidenceofurinaryincontinencerangesfrom3.7%
to 4.8% [26, 27, 29]. The causes of incontinence include
sphincter muscle destruction, disruption of the pudendal
nerve, and urethral sloughing.
There are some complications speciﬁc to cryother-
apy including tissue sloughing, urethral stricture, pelvic
and rectal pain, rectourethral ﬁstula [33], and penile
numbness [19]. Penile and scrotal swelling within several
weeks after cryotherapy is reported as a rare complication.
Hydronephrosis or small bowel obstruction as uncommon
complications results from the extensive freezing and deep
insertion of cryoprobe [34]. The risks of these compli-
cations have decreased with advances in technology, such
as urethral warming techniques, and improved patient
selection.
6.High-Intensity-FocusedUltrasound(HIFU)
The ﬁrst report describing HIFU using the transrectal probe
of benign prostate hyperplasia appeared in the mid-1980s
[35], and an attempt to treat localized prostate cancer was
reported in 1995 [36]. Diagnostic ultrasound usually uses
frequencies in the range of 1 to 20MHz, but transrectal
HIFU uses sound waves with frequencies of 0.8 to 3.5MHz
and can achieve coagulative necrosis and the destruction of
the targeted tissue through hyperthermia in two ways. The
two mechanisms of tissue damage are by the conversion of
mechanical energy into heat and inertial cavitation. Firstly,
ultrasound energy is concentrated and tissue absorption of
the focused ultrasound wave generates temperatures that4 Advances in Urology
exceed 80◦C, which denature proteins and destroy lipid-
based membranes, and this process ﬁnally results in instan-
taneous and irreversible coagulative necrosis. Secondly, the
alternating cycles of compression and rarefaction develop
inertial cavitation eﬀect causing additional damage to the
prostate and periprostatic tissue. Histologically, homoge-
neous coagulative necrosis developed in the damaged tissue
with an inﬂammatory response that follows leading to for-
mationofgranulation[37].Currently,twosystemsincluding
Sonoblate-500producedbyFocusSurgery(Indianapolis,IN)
and Ablatherm produced by EDAP TMS (Lyons, France)
for delivery of HIFU are available. The treatment area is
heated for 3 seconds and cooled for 6 seconds with real
time images. The energy decreases sharply outside the target
zone; thus the surrounding tissues are minimally aﬀected.
Days to months are required for necrosis and cavitation to
occur, and the prostate gland shrinks a small size over 3
to 6 months after the procedure. Due to the limits of the
ultrasound wave, there is the diﬃculty in ablating the whole
prostategland,especiallyinalargeprostate(>40mL)andthe
diﬃculty in ablating anterior cancers[38]. Hormone therapy
or transurethral resection of the transitional zone may be
useful in overcoming the diﬃculty of reaching the anterior
zone.
7.PatientSelection
In general, primary HIFU is suitable for older patients
(over 70 years) with low- and intermediate risk groups.
HIFU may be used to treat prostate cancer, either as a
primary or as salvage therapy. There is an upper limit
to prostate gland size of 40mL due to focal length of
the probe. In this case, a TURP before HIFU can be of
beneﬁt to reduce prostate size and can also reduce morbidity
and indwelling catheter time. In general, the prostate with
highly calciﬁcations (>1cm) should be contraindication
because these will obscure ultrasonographic visualization. In
some cases TUR of large calciﬁcations may be performed
before HIFU. As with cryotherapy, HIFU may have speciﬁc
advantages in selecting patients with certain comorbidity
includingthosewhocannottolerateradicalprostatectomyor
radiation therapy.
8. ClinicalOutcomes
As the data on HIFU as salvage therapy were limited, we
focused on HIFU as primary therapy. The combination of
PSA value and prostate biopsy is used to deﬁne recurrence
after HIFU. A multicenter trial with the results of using the
Ablatherm was reported in 2003 [39]. Although 28% of the
patients required two treatment sessions, 87% of the patients
had a negative biopsy with 92%, 86%, and 82% in the low-,
intermediate-, and high-risk groups, respectively. Mean PSA
nadir in the low-, intermediate-, and high-risk groups was
1.3ng/mL, 1.4ng/mL, and 3.1ng/mL, respectively, and a
median PSA nadir of 0.4ng/mL was achieved at a minimal
follow-up of 6 months. Gelet et al. reported the long-
term results in patients with low-risk disease. Patients with
preoperative PSA less than 10ng/mL demonstrated negative
biopsy of 78% and 5-year disease-free survivals of 83%.
For those with intermediate- and high-risk groups, the
disease-free survival rate was 53% and 36%, respectively
[40]. Blana et al. also analyzed a large cohort in patients
with low- and intermediate- risk disease. The 5-year disease-
free probability was 66%, and 28% of the low-risk disease
developed treatment failure [41] .T h en e g a t i v eb i o p s yr a t e
after the procedure ranges from 55% to 100% in recent trials
including clinical T1 to T3 stages. Higher clinical T stage and
larger prostate size were positively associated with a risk of
both PSA failure and positive biopsy rate after HIFU [39, 42–
44].
9. Complications
Transient urinary retention arising from swelling of the
prostateafterHIFUisthecommoncomplication,whichmay
require prolonged catheterization or cystostomy drainage
[39]. Prolonged retention ranged from 6% to 32% [39, 42–
44]. A high degree of urethral stenosis near the verumon-
tanum and bladder outlet obstruction was seen, which are
late complications of HIFU. The recent reported incidence
of urethral stenosis ranged from 2% to 17% [39, 42–44]. De
novo erectile dysfunction and impotence were also known to
occur at 24%–77% of those who were potent preoperatively.
The use of a pulsed-wave Doppler ultrasound system to
visualize the neurovascular bundles during treatment may
improve this outcome. Mild to moderate stress incontinence
rates after HIFU ranged from 6% to 14% of patients
in earlier series, but this has decreased over the years
with next-generation HIFU devices [39, 42–44]. Severe
incontinence developed in 1%–5% requiring intervention
[39, 42–44]. Stress incontinence, urethral stenosis, and
bladder outlet obstruction were reported to be decreased
by TURP before HIFU [45]. Therefore, TURP may be
indicated before HIFU; however, TURP appears to have
no eﬀect on cancer control including PSA nadir, negative
biopsy rate, and biochemical failure. There were some
serious complications speciﬁc to HIFU including rectal wall
burn and rectourethral ﬁstula before the use of the rectal
cooling device and robotic control system of rectal distance
[46]. Current results report on the complications seen with
HIFU as whole gland therapy; however, one can expect
lower rates of complications with HIFU as targeted focal
therapy.
10.Vascular-TargetedPhotodynamic
Therapy (VTP)
VTP is an investigational ablative technology which employs
the use of photosensitizing properties that is selectively taken
up by prostate cancer cells and produces radical oxygen
species upon exposure to light of a speciﬁc wavelength which
results in the destruction of the tissue. The ﬁrst report
describing photodynamic therapy for prostate cancer with
light-sensitive agent (either hematoporphyrin derivative or
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appeared in 1990 [47]. The photosensitizers have taken a
long time to be cleared from the body and accumulated
in the skin. To avoid sunburn-like reaction patients must
have been covered from sunlight for a several weeks after
treatment [48]. Recent advances in photodynamic therapy
have led to improvements of the synthesis of new generation
photosensitizers with more excellent stability and shorter
half-lives with faster metabolism. The rapid clearance of
these new agents from the circulation and then from the
liver could negate the need to avoid exposure to sunlight
for long periods. Vascular acting photosensitizers currently
under investigation are Tookad (WST09: padoporﬁn; palla-
dium bacteriopheophorbide) and its water-soluble deriva-
tive WST11 (padeliporﬁn; palladium bacteriopheophorbide
monolysotaurine) produced by Steba Biotech (The Nether-
lands), which are the most widely used new generation
photosensitizers. Both WST09 and WST11 remain conﬁned
to the vascular bed [49].
A photosensitizer is injected intravenously and is dis-
tributed throughout the body during treatment. Under
ultrasound guidance, small energy-delivering probes can
be positioned in the prostate using a needle placement
grid developed for brachytherapy. VTP usually uses an
intravenously administered WST09 that absorbs light in the
visible near infrared wavelength with maximum light energy
absorption at 763nm. This long light absorption wavelength
allows for a deeper light penetration into tissues. A photo-
sensitizer enhances sensitivity of the tumor vasculature to
lightenergy.Damagetothevascularendotheliumisfollowed
by platelet aggregation and vascular coagulation round the
tip of the ﬁber with subsequent localized tissue necrosis
[50].
11. ClinicalOutcomes
A ﬁrst multicenter phase I/II clinical trial reported the safety
and eﬃcacy of VTP using WST09 in patients with recurrent
localized prostate cancer after external beam radiotherapy
including clinical T1 and T2 stages. VTP-treated lesions
were generally ellipsoidal on MRI and repeat target biopsies
at 6 months, which correlated with devascularized zones
on MRI, showed ﬁbrosis, and were devoid of cancer [51–
53]. In contrast, no eﬀective areas on MRI included the
presence of cancer. Since VTP did not attempt to ablate
whole prostate gland in this trial, the PSA changes only
reﬂect the destruction of prostate tissue and not necessarily
of prostate cancer. There were no serious adverse events
including cutaneous photosensitivity, and neither urinary
nor erectile function was compromised in the long-term
follow-up up to 6 months after the procedure. In general,
VTP using WST09 was performed safely and well tolerated
with no serious adverse events including incontinence, tissue
sloughing, and rectal injury [51]. This safety may be a result
of VTP using the vascular targeting nature of WST09 of the
limited light exposure of the urethra andrectum.In contrast,
a patient with meso-tetra-hydroxyphenyl chlorine (mTHPC,
Foscan) developed a rectourethral ﬁstula after assessing
abnormal rectal mucosa by a rectal biopsy [54]. And other
side eﬀects including urinary retention, temporary stress
incontinence, and urethralstricture werenoted in VTP using
mTHPC [54].
12.Up-to-Date Biopsy Technique and
ImagingModality
The success of focal therapy is obviously dependent on
the ability to detect the extent of prostate cancer and
then accurately target it. The problem is that we have lack
of agreement on candidate selection protocols for focal
therapy. This point derives from the lack of an adequate
biopsy techniques and imaging modality that could reliably
detect prostate cancer foci. There is no clear answer as to
what is the optimal biopsy strategy to be used to evaluate
potential candidates for focal therapy. However, biopsy is
the only accurate method for prostate cancer laterality.
There are insuﬃcient data on standard sextant biopsy to
assure correct localization of prostate cancer foci [55].
Even extended TRUS-guided saturation biopsy has appeared
to be inadequate in the proper selection of patients for
focal therapy [56]. At present, transperineal 3D mapping
biopsy has been proposed as a way to more accurately
predict prostate cancer focality [57, 58]. In this approach,
samples are taken every 5mm throughout the volume of the
prostate using a brachytherapy template grid under TRUS
guidance. Using transperineal 3D mapping biopsy, 61.1%
of patients with unilateral cancer on TRUS biopsy were
positive bilaterally, and 22.7% were upstaged by Gleason
scores[58].Therefore,transperineal3Dmappingbiopsymay
provide the most accurate cancer localization information
and appear essential for proper patient selection for focal
therapy. The chief objection to this type of procedure is
time demandandcostinvolved. Thus, analternativeimaging
technology for tumor detection and localization must be
considered. MRI is the gold standard over the past decade.
Improvements in functional MRI techniques include MR
spectroscopy (MRS), diﬀusion-weighted imaging (DWI),
and dynamic contrast enhanced MRI (DCE). Each of these
three techniques has improved tumor detection compared
with standard T2-weighted imaging (T2WI) alone [59–61].
The combined diagnostic accuracy of T2WI, DCE, and
MRS enabled tumor detection with signiﬁcant independent
and additive predictive value [62]. Multiparametric MRI
(MpMRI) is currently considered the state of the art for
prostate imaging with reasonable sensitivity and speciﬁcity
values.
13. Conclusion
The recent downward stage migration favoring early dis-
ease has revealed new treatment options for patients with
localized prostate cancer. And the therapeutic dilemma
between active surveillance and radical therapy and the
signiﬁcant morbidity associated with radical therapy have
led to development of minimally invasive focal therapy such
as cryotherapy, HIFU, and VTP. Cryotherapy and HIFU
emerged as pioneers in focal therapy showed a lot of promise6 Advances in Urology
but still need a long-term follow-up for assessing quality
of life and cancer-speciﬁc and overall survival before the
indications for primary or salvage therapy can be expanded.
VTP as an investigational therapy needs careful patient
speciﬁc planning since signiﬁcant variability in the dose
distribution and consequent tissue response. The goal of
focal therapy is to selectively ablate known disease, while
minimizing lifetime morbidity without compromising life
expectancy. To reduce the side eﬀects and maintain a
favorable quality of life after focal treatment, we must pursue
alternative techniques such as a subtotal gland treatment,
hemiablation, or focal targeted ablation. The ideal patients
for focal therapy appear to be ones with low-grade, low-
volume disease that can be easily characterized. In addition,
focal therapy may be potentially useful in salvage therapy.
Since prostate cancer is commonly a multifocal disease,
standard or extended biopsy techniques are not capable
of reliably identifying all existing cancer. Therefore, the
technical innovations such as 3D-mapping prostate biopsy,
histoscan, and MpMRI are applied to accurately detect
prostate cancer foci. A further novel imaging tool for iden-
tifying individuals is desirable in careful preoperative patient
selection.
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